{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:22:07Z","timestamp":1777497727270,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["H30MC24045"],"award-info":[{"award-number":["H30MC24045"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40259-023-00615-4","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T15:30:05Z","timestamp":1690299005000},"page":"595-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-8958","authenticated-orcid":false,"given":"Courtney D.","family":"Thornburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-4703","authenticated-orcid":false,"given":"Dana H.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-6322","authenticated-orcid":false,"given":"Annette","family":"von Drygalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"issue":"1","key":"615_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Fischer K, Hart DP, et al. Haemophilia Nat Rev Dis Primers. 2021;7(1):45. https:\/\/doi.org\/10.1038\/s41572-021-00278-x.","journal-title":"Haemophilia. Nat Rev Dis Primers."},{"key":"615_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","volume":"397","author":"ME Mancuso","year":"2021","unstructured":"Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397:630\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(20)32722-7.","journal-title":"Lancet"},{"issue":"9","key":"615_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","volume":"22","author":"SW Pipe","year":"2022","unstructured":"Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Exp Opin Biol Ther. 2022;22(9):1099\u2013115. https:\/\/doi.org\/10.1080\/14712598.2022.2002842.","journal-title":"Exp Opin Biol Ther."},{"key":"615_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13998","volume":"26","author":"JM Soucie","year":"2020","unstructured":"Soucie JM, Miller CH, Dupervil B, et al. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centers. Haemophilia. 2020;26:487\u201393. https:\/\/doi.org\/10.1111\/hae.13998.","journal-title":"Haemophilia"},{"issue":"5","key":"615_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","volume":"133","author":"AC Weyand","year":"2019","unstructured":"Weyand AC, Pipe SW. New therapies for hemophilia. Am Soc Hem. 2019;133(5):389\u201398. https:\/\/doi.org\/10.1182\/blood-2018-08-872291.","journal-title":"Am Soc Hem"},{"key":"615_CR6","unstructured":"Eloctate\u00ae (antihemophilic factor (recombinant), Fc fusion protein) Prescribing Information. 2023. Bioverativ Therapeutics, Inc. Waltham, MA 02451."},{"key":"615_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A Von Drygalski","year":"2023","unstructured":"Von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis in patients with severe hemophilia A. N Engl J Med. 2023;388:310\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2209226.","journal-title":"N Engl J Med"},{"issue":"11","key":"615_CR8","first-page":"1","volume":"20","author":"A Von Drygalski","year":"2022","unstructured":"Von Drygalski A. Editor: Kessler CM. Beyond factor replacement therapy: new and experimental agents for hemophilia. Clin Adv Hem Onc. 2022;20(11):1\u20133.","journal-title":"Clin Adv Hem Onc."},{"issue":"3","key":"615_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood.2019000658","volume":"134","author":"HM Van den Berg","year":"2019","unstructured":"Van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134(3):317\u201320. https:\/\/doi.org\/10.1182\/blood.2019000658.","journal-title":"Blood"},{"issue":"2","key":"615_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.18495","volume":"200","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Lamas JL, Morales JC, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023;200(2):240\u20138. https:\/\/doi.org\/10.1111\/bjh.18495.","journal-title":"Br J Haematol"},{"key":"615_CR11","unstructured":"Novo Nordisk Canada Inc. Press Release: Health Canada approves Alhemo\u2122, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors. April 17, 2023. Cision PR Newswire. https:\/\/www.newswire.ca\/news-releases\/health-canada-approves-alhemo-tm-the-first-subcutaneous-prophylactic-treatment-for-people-living-with-hemophilia-b-with-inhibitors-842083225.html. Accessed 14 June 2023."},{"key":"615_CR12","unstructured":"Waldron J. Press Release. Novo Nordisk\u2019s Hemlibra rival faces another approval setback as FDA raises dosing, manufacturing questions. May 4, 2023. Fierce Biotech. https:\/\/www.fiercebiotech.com\/biotech\/novo-nordisks-hemlibra-rival-faces-another-approval-setback-fda-raises-dosing-queries. Accessed 14 June 2023."},{"key":"615_CR13","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7412.S1-006","author":"SA Roberts","year":"2011","unstructured":"Roberts SA, Dong B, Firrman JA, et al. Engineering factor VIII for hemophilia gene therapy. J Genet Syndr Gene Ther. 2011. https:\/\/doi.org\/10.4172\/2157-7412.S1-006.","journal-title":"J Genet Syndr Gene Ther."},{"key":"615_CR14","unstructured":"Roctavian\u2122 (valoctocogene roxaparvovec) Summary of Product Characteristics. 2022. BioMarin international Ltd. Shanbally, Ringaskiddy, Ireland."},{"key":"615_CR15","unstructured":"Hemgenix\u00ae (etranacogene dezaparvovec-drlb) Prescribing Information. 2022. CSL Behring LLC. King of Prussia, PA, USA."},{"issue":"3","key":"615_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep01832","volume":"2013","author":"D Sen","year":"1832","unstructured":"Sen D, Balakrishnan B, Gabriel N, et al. Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep. 1832;2013(3):1\u20136. https:\/\/doi.org\/10.1038\/srep01832.","journal-title":"Sci Rep"},{"issue":"7\u20138","key":"615_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2021.287","volume":"33","author":"R Klamroth","year":"2022","unstructured":"Klamroth R, Hayes G, Andreeva T, et al. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gen Ther. 2022;33(7\u20138):432\u201341. https:\/\/doi.org\/10.1089\/hum.2021.287.","journal-title":"Hum Gen Ther."},{"key":"615_CR18","unstructured":"Hemgenix\u00ae (etranacogene dezaparvovec-drlb) Summary of Product Characteristics. 2023. CSL Behring GmbH. Marburg, Germany."},{"issue":"11","key":"615_CR19","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2113708.","journal-title":"N Engl J Med"},{"key":"615_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388:694\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa2211075.","journal-title":"N Engl J Med"},{"key":"615_CR21","unstructured":"Eggan K. BioMarin. Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for valoctocogene roxaparvovec insertion in altering cell growth. Presented Monday, May 9, 2022 at the World Federation of Hemophilia 2022 World Congress. May 8-11, 2022. Montreal, Canada. https:\/\/investors.biomarin.com\/2022-05-05-BioMarin-to-Present-Findings-from-Ongoing-Studies-of-Valoctocogene-Roxaparvovec,-Investigational-Gene-Therapy,-at-the-World-Federation-of-Hemophilia-2022-World-Congress,-May-8-11,-2022,-Including-Five-Platform-Presentations. Accessed 24 June 2023."},{"key":"615_CR22","unstructured":"BioMarin Update for the Hemophilia Community. Clinical Development Program Update. September 12, 2022. BMN 270, valoctocogene roxaparvovec. https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/BioMarin%20Hemophilia%20NORAM%20Program%20Update%20for%20Patient%20Associations%2012SEP22.pdf. Accessed 21 June 2023."},{"key":"615_CR23","unstructured":"Bigica A. Press Release. CGTlive. BioMarin to investigate B-ALL case in val-rox gene therapy clinical trial. September 14, 2022. https:\/\/www.cgtlive.com\/view\/biomarin-to-investigate-b-all-case-in-val-rox-gene-therapy-clinical-trial. Accessed 21 June 2023."},{"key":"615_CR24","unstructured":"BioMarin Pharmaceutical Inc. Press Release: BioMarin announces advances in FDA review of Roctavian\u2122 (valoctocogene roxaparvovec) for adults with severe hemophilia A. November 23, 2022. Cision PR Newswire. at https:\/\/www.prnewswire.com\/news-releases\/biomarin-announces-advancements-in-fda-review-of-roctavian-valoctocogene-roxaparvovec-for-adults-with-severe-hemophilia-a-301685915.html. Accessed 23 Jan 2023."},{"key":"615_CR25","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388:706\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2211644.","journal-title":"N Engl J Med"},{"key":"615_CR26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008886","author":"A Von Drygalski","year":"2022","unstructured":"Von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv. 2022. https:\/\/doi.org\/10.1182\/bloodadvances.2022008886. (Epub ahead of print).","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"615_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","volume":"132","author":"AC Nathwani","year":"2018","unstructured":"Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d and safety and efficacy of gene transfer. Blood. 2018;132(Suppl. 1):491. https:\/\/doi.org\/10.1182\/blood-2018-99-118334.","journal-title":"Blood"},{"key":"615_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/26330040211058896","volume":"2","author":"CD Thornburg","year":"2021","unstructured":"Thornburg CD. Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis. 2021;2:1\u201314. https:\/\/doi.org\/10.1177\/26330040211058896.","journal-title":"Ther Adv Rare Dis."},{"issue":"21","key":"615_CR29","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood.2019002867","volume":"135","author":"J Poothong","year":"2020","unstructured":"Poothong J, Pottekat A, Siirin M, et al. Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. Blood. 2020;135(21):1899\u2013911. https:\/\/doi.org\/10.1182\/blood.2019002867.","journal-title":"Blood"},{"issue":"21","key":"615_CR30","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1182\/blood.2020005450","volume":"135","author":"DE Sabatino","year":"2020","unstructured":"Sabatino DE. Comment on Poothong et al, page 1899: Clogging up the pipeline: factor VIII aggregates. Blood. 2020;135(21):1825\u20137. https:\/\/doi.org\/10.1182\/blood.2020005450.","journal-title":"Blood"},{"issue":"11","key":"615_CR31","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jval.2021.05.008","volume":"24","author":"LP Garrison","year":"2021","unstructured":"Garrison LP, Pezalla E, Towse A, et al. Hemophilia gene therapy value assessment: methodological challenges and recommendations. Value Health. 2021;24(11):1628\u201333. https:\/\/doi.org\/10.1016\/j.jval.2021.05.008.","journal-title":"Value Health."},{"key":"615_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14706","author":"J Limjoco","year":"2022","unstructured":"Limjoco J, Calatroni A, Aristizabal P, et al. Gene therapy preferences and informed decision-making: results from the National Hemophilia Foundation Community Voices in research survey. Haemophilia. 2022. https:\/\/doi.org\/10.1111\/hae.14706.","journal-title":"Haemophilia"},{"issue":"8","key":"615_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/2040620718784830","volume":"9","author":"F Nossair","year":"2018","unstructured":"Nossair F, Thornburg CD. The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Ther Adv Hematol. 2018;9(8):239\u201349. https:\/\/doi.org\/10.1177\/2040620718784830.","journal-title":"Ther Adv Hematol."},{"issue":"1","key":"615_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2478\/jhp-2022-0021","volume":"9","author":"D Noone","year":"2023","unstructured":"Noone D, Astermark J, O\u2019Mahony B, et al. The journey of gene therapy in haemophilia\u2014putting the patient at the centre of the hub and spoke model. J Haemophilia Practice. 2023;9(1):156\u201366. https:\/\/doi.org\/10.2478\/jhp-2022-0021.","journal-title":"J Haemophilia Practice"},{"key":"615_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40271-019-00395-6","volume":"13","author":"EC Van Balen","year":"2020","unstructured":"Van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: a qualitative study. The Patient. 2020;13:201\u201310. https:\/\/doi.org\/10.1007\/s40271-019-00395-6.","journal-title":"The Patient."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00615-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00615-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00615-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T14:17:33Z","timestamp":1692195453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00615-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00615-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"7 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by funding from the Health Resources and Services Administration (HRSA) H30MC24045.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Courtney D. Thornburg has had institutional grant funding from BioMarin Pharmaceuticals. Courtney D. Thornburg has received honoraria for participating in scientific advisory panels, consulting, and speaking engagements for CSL Behring, HemaBiologics, Genentech, Pfizer, Sanofi Genzyme, and Spark Therapeutics. Courtney D. Thornburg has received fees for participation in data monitoring board from BlueBird Bio. Dana H. Simmons declares that she has no conflict of interest. Annette von Drygalski has received honoraria for participating in scientific advisory board panels, consulting, and speaking engagements for BioMarin, Regeneron, Pfizer, Bioverativ\/Sanofi, CSL Behring, NovoNordisk, Spark Therapeutics, Genentech and UniQure. Annette von Drygalski is a co-founder and member of the Board of Directors of Hematherix LLC., a biotechnology company that is developing\u00a0<sup>super<\/sup>FVa therapy for bleeding complications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"None required, this work represents a review of available evidence.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Patient Consent"}},{"value":"Not applicable, this work represents a review of available evidence.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors listed made substantial contributions to this work according to ICMJE standards, drafted or revised the manuscript, approved the version to be published, and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}